Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by China Medical University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT01249066
First received: November 24, 2010
Last updated: November 26, 2010
Last verified: September 2010
  Purpose

AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.


Condition
Lung Adenocarcinoma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Estimated Enrollment: 100
Study Start Date: September 2010
  Eligibility

Ages Eligible for Study:   25 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Lung cancer received lobectomy in CMUH

Criteria

Inclusion Criteria:

  • Lung cancer received operation lobectomy in CMUH

Exclusion Criteria:

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01249066

Locations
Taiwan
Fang Hsin Yuan Recruiting
Taichung, Taiwan, 404
Contact: Hsin-Yuan Fang, MD    +886422052121 ext 1638    d93421104@ntu.edu.tw   
Sponsors and Collaborators
China Medical University Hospital
  More Information

No publications provided

Responsible Party: Fang Hsin-Yuan/Director, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01249066     History of Changes
Other Study ID Numbers: DMR99-IRB-096
Study First Received: November 24, 2010
Last Updated: November 26, 2010
Health Authority: Taiwan: Institutional Review Board

Keywords provided by China Medical University Hospital:
AMP-activated protein kinase
lung adenocarcinomas
Prognosis
Observation study

Additional relevant MeSH terms:
Adenocarcinoma
Lung Neoplasms
Carcinoma
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on October 23, 2014